The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
 
F. Stephen Hodi
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck Sharp & Dohme; Novartis
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
John A. Thompson
Honoraria - Amgen
Research Funding - Agensys; Merck
Travel, Accommodations, Expenses - Amgen
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Prometheus (Inst)
 
Wen-Jen Hwu
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck/Schering Plough
 
Donald P. Lawrence
No Relationships to Disclose
 
Nancy Ann Dawson
Honoraria - Amgen; Astellas Pharma; Bayer; Eisai; Genentech/Roche; Janssen Biotech; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Janssen Scientific Affairs
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Eisai; Genentech/Roche; Janssen Biotech; Novartis; Pfizer; Sanofi
Research Funding - Acceleron Pharma (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Pfizer (Inst); Roche/Genentech (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Deborah Jean Lee Wong
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - ARMO BioSciences; AstraZeneca/MedImmune; BioMed Valley Discoveries; Kura Oncology; Merck Serono; Merck Sharp & Dohme
 
Shailender Bhatia
Research Funding - Bristol-Myers Squibb (Inst); Conkwest (Inst); EMD Serono (Inst); Immune Design (Inst); Merck (Inst); OncoSec (Inst)
Travel, Accommodations, Expenses - EMD Serono
 
Marihella James
No Relationships to Disclose
 
Xinxin Shu
No Relationships to Disclose
 
Blanca Homet Moreno
Employment - Merck
Stock and Other Ownership Interests - Merck
Honoraria - Merck
 
Nageatte Ibrahim
Employment - Merck
Stock and Other Ownership Interests - GlaxoSmithKline; Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
Patents, Royalties, Other Intellectual Property - Merck
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; Lilly; Merck; Novartis
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Alkermes; Amgen; Bristol-Myers Squibb; C-Cam; Genentech; Genoptix; GlaxoSmithKline; Infinity Pharmaceuticals; Lilly; Merck; Nektar; Novartis; Pfizer; X4 Pharma